According to a recent LinkedIn post from BioSpectator Inc, new phase 2 data for a triple agonist obesity drug candidate from The United Bio-Technology, UBT251, are beginning to emerge. The post notes that, at 24 weeks, the GLP-1/GIP/GCG triple agonist reportedly achieved up to 19.7% weight loss, although detailed data have not yet been disclosed.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights that these preliminary results appear competitive versus Eli Lilly’s leading triple agonist candidate retatrutide, which showed up to 17.5% weight loss at the highest 12 mg dose in a phase 2 trial. However, the post also underscores Lilly’s significant lead, with an initial phase 3 readout already reported in December and seven phase 3 studies expected to complete within this year, suggesting a challenging environment for later entrants and partners such as Novo Nordisk that are seeking next-generation obesity assets.